Trial Profile
Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients With Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Dec 2023
Price :
$35
*
At a glance
- Drugs Maplirpacept (Primary) ; Azacitidine; Azacitidine; Bortezomib; Carfilzomib; Dexamethasone; Dexamethasone; Isatuximab; Nivolumab; Pembrolizumab; Rituximab; Venetoclax
- Indications Acute myeloid leukaemia; Diffuse large B cell lymphoma; Erdheim-Chester disease; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; Multiple myeloma; Mycosis fungoides; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms TTI-622-01
- Sponsors Pfizer; Trillium Therapeutics Inc
- 21 Dec 2023 Planned End Date changed from 25 Mar 2025 to 11 Sep 2024.
- 21 Dec 2023 Planned primary completion date changed from 25 Mar 2024 to 11 Sep 2024.
- 30 Oct 2023 Study phase changed from Phase 1/2 to Phase 1.